Nektar Therapeutics (NKTR)

[Monksdream]

NKTR new 52 week high

[Monksdream]

NKTR under $2

[glenn1919]

NKTR......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

[Monksdream]

NKTR new 52 hi

[TrendTrade2016]

NKTR here we go. Every time I go higher with my bench press this stocks follows

[TrendTrade2016]

NKTR setting up here

[TrendTrade2016]

NKTR...MASSIVE VOLUME

[TrendTrade2016]

NKTR...PUSHING TO THE TOP OF THE WEEKLY CLOUD....WILL SHE BREAK FOR BLUE SKY!!!

[glenn1919]

NKTR........................................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

[Monksdream]

NKTR new 52 hi

[Monksdream]

NKTR new 52 hi

[glenn1919]

NKTR..............................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

[Awl416]

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

[glenn1919]

NKTR.......................................https://stockcharts.com/h-sc/ui?s=NKTR&p=W&b=5&g=0&id=p86431144783

[Monksdream]

NKTR 10Q March 4

[Monksdream]

NKTR new 52 week low

[Monksdream]

NKTR new 52 week low

[seve333]

Stock is in the toilet again they need an actual settlement from LLY go get the stock moving and so far crickets.

[sc00pnDump]

Nice stock options 0.68 @ 85,000 shares

[81vette]

Holding up amazingly well,might continue up

[Invest-in-America]

NKTR: Now suing Eli Lilly, in conjunction with today's earlier (Dermatitis) news package.

[Invest-in-America]

NKTR: This one ain't over until the FAT PHARMACISTS sing!!

[Invest-in-America]

NKTR: Huge numbers of Peeps MISSED your brilliant pick here today, Dude!!! (Talk about 'easy money'!!)

[AJ Freely]

$NKTR - 👆Up 15.8% Pre-Market/ Current Price $0.61
Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in '22 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

[The Night Stalker]

cheap

[The Night Stalker]

cheap

[DavidTrader]

pincher chart on the daily and weekly, I think this could easily run to $1.50

[Lilman72003]

Hmmm just crickets around here, I don’t mind arriving early to the party

[DewDiligence]

NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures in RCC and bladder cancer:

https://finance.yahoo.com/news/nektar-bristol-myers-squibb-announce-203000621.html

Nektar Therapeutics and Bristol Myers Squibb (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo. These studies and all other ongoing studies in the program will be discontinued.

Bempeg previously failed in a phase-3 trial in combination with Opdivo in melanoma (#msg-168191364), so today’s news is three strikes and you’re out!

Rarely has a cancer drug failed so utterly and completely to live up to initial expectations (#msg-138532013). NKTR’s share price is down 96%(!) from its 2018 high.

[Frankestin]

Ouch Ouch
how it hurts here!
I don't even see a reason to hope it goes up!
How much cash do they have?
But that's enough until the end of 2024 if that's okay ...
THE MANAGER OF NEKTAR THERAPEUTICS SAYS TO PREPARE A PLAN THAT HAS THE OBJECTIVE OF ESTABLISHING THE MINIMUM CASH TRACK UNTIL AT LEAST 2024 - CONF. CALL
As the drug fails to meet any of its goals, Nektar said he would consider curbing his cash spending, which was about $ 800 million at the end of December.


Last week, brokerage agency Oppenheimer estimated that worldwide un-risk-adjusted bempegaldesleukin sales could reach $ 3.7 billion in 2038. (news)

I know of one recently approved that will do 3B by 2026

[DewDiligence]

NKTR’s Bempeg fails as addend to Opdivo in first-line melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-nektar-announce-105900961.html

Bristol Myers Squibb and Nektar Therapeutics today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma. Following a review of the study for efficacy and safety by an independent Data Monitoring Committee (DMC), Bristol Myers Squibb and Nektar were informed that the study did not meet the primary endpoints of progression-free survival (PFS) and objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR). The DMC notified the companies that the third primary endpoint of overall survival (OS) did not meet statistical significance at the first interim analysis.

Given there was no additional clinical benefit in the doublet therapy arm compared to the monotherapy arm for the primary endpoints of PFS and ORR, and based on the data reviewed by the DMC, the companies have decided to unblind the trial and to perform no additional analyses for the OS endpoint.

Additionally, based on the results from PIVOT IO-001, the companies have also made the decision to discontinue enrollment and unblind the ongoing PIVOT-12 study in adjuvant melanoma, which is evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo compared to Opdivo monotherapy in patients at high risk for recurrence after complete resection of melanoma.

[DewDiligence]

NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer:

https://finance.yahoo.com/news/nektar-announces-agreement-phase-2-130000352.html

NKTR is receiving no cash from MRK—only free drug for use in the trial. Rather, unding for the trial is being provided by NKTR’s financing deal with SJC Pharma (https://finance.yahoo.com/news/nektar-announces-collaboration-sfj-pharmaceuticals-125900283.html ).

Note that the 3-year PD-(L)1 exclusivity period of the BMY/NKTR collaboration, which was announced on 2/14/18, has now expired, enabling NKTR to test Bempeg with any PD-(L)1 agent of its choosing.

p.s. Even after today’s pop, NKTR’s share price is down about 70% from the day of the BMY announcement three years ago.

[ClayTrader]

* * $NKTR Video Chart 01-15-2020 * *

Link to Video - click here to watch the technical chart video

[DewDiligence]

Comments on the JPM webcast: #msg-153299506.

[DewDiligence]

We talk about NKTR a little on #board-1418.

[Sluicebox]

On what board are people discussing Nektar ?

[czni]

Yea, bloody taa for !?
I will check back. Those were shot down before I could focus on them. It’s just that one ticker.
A big pharm company is going to buy 11% of a biotech company.
Whatever you do
Find it.
Two day jump could mean over 50% growth before all the old-timers start jumping out because they were holding this in 1912. BC :)
Im an old timer so I can say this.
Dont miss this one!
And please dont let me miss.
I have an entire day on this :(

Once we are free of that, all of the new people will be coming in by Thursday.

Come on people? It’s really important.

[czni]

Well if that wasn’t the strangest thing on the planet?

My plan was to research the heck out of this thing and share it with who is on this weekend.

This way we can start Monday ahead of the pac.

There really are only two questions that I would like answers to. This company of course and it’s future and of course what my other message said. Much obliged and whatever I find out, it stays right here.

[czni]

I have been doing a lot of studying on this company. I know that we are closer to the 52 week wow than the high. This sector is supposed to be picking up in this company looks pretty decent. What can we expect as far as mergers or stock forecast for 2020? Pretty legitimate not asking for million dollar tickers...

Where are we and where are we going....

[czni]

You saw that, yes.
thanks but I do not have a photographic memory unfortunately.

Looks like you were taken down.
Fast!
But we’re smarter than that

[czni]

That’s why I love this board. You don’t have to deal with scammers or flippers or anybody trying to feed you a line just to buy end so they can dump. You guys have already been very hospitable. There’s a certain company farmer that is going to buy 11% of a biotech company. If we can find out the ticker symbol on this biotech company,
it’s worth about 180% in the first three days and a bunch more coming after.

Right now the biotech price is very low.

If we can keep it to just us for now The ones here that are interested can get in before the world finds out about it.
Trust me,
I spent four hours digging and digging to find this ticker.

Nobody is leaking it.

Come on guys,
dig a little bit with me.
I promise you it will be worth it!

I put a lot of time in. As soon as I find it I will share on this page. And only this page! It’ll be taken down by Monday so it needs to happen. Everybody takes 15 minutes.

With the experience reading this,
I have no question we can get this ticker symbol.

Monday morning we will be locked and loaded!

Oh yes!

[czni]

Hey gang,
Im a quiet holder but have a question driving me crazy!

The MU wait for chips was so Ridiculous even after having this giant to do in Las Vegas.

Do you know the people that paid all around the world to go to Las Vegas just to hear that ticker symbol was not given out at that meeting?

You had to purchase his book in order to get it.

As soon as I dug it up,
I gave it out to everybody.

Now this big Pharma company whoever they are,
are getting ready to purchase 11% of a biotech company.

It has not happened yet but I’m looking for the ticker symbol for the biotech company.

The Pharma company is already out of reach but the biotech company There’s a couple of very important patents making the merger happen quicker.

Does anybody know the biotech company ticker symbol?

I need something that’s going to climb and keep climbing.

On a sidenote,
before my wife finds out I lost just about everything on the stock that should have gone to 50 plus wish i had known they had trouble with their CEO and the CFO having private meetings putting the company under investigation and stopping all Trading for over a month. It trades for 1/10000 of a penny now. I put everything on it!!!

. If you can throw that out to me, you could possibly change my marriage LOL.
Thanks very much and good skill to everyone!
The only job that I have ever had that did not look forward to the weekends!!! Happy hunting!
I dont have pm but please use it if you can. Happy Holidays!

Thanks gang

Sweet Virginia Breeze

[Clemdane]

Thinking people are just taking profits today?

[whytestocks]

News: $NKTR 2 Stocks That Soared Monday While the Market Slumped

Are you in the holiday spirit yet? Well, obviously the stock market isn't, given its tepid performance on Monday. Most major indexes sagged, with many stocks sinking along with them. Monday's a good day to go positive, though, so I'm going to highlight two stocks that bucked this trend and incr...

Got this from NKTR - 2 Stocks That Soared Monday While the Market Slumped

[whytestocks]

News: $NKTR Why Nektar Therapeutics Stock Popped Today

Shares of Nektar Therapeutics (NASDAQ: NKTR) were up 11.4% as of 3:15 p.m. EST on Monday. The biotech presented data Sunday evening at the American Society of Hematology (ASH) annual meeting from a preclinical trial evaluating immunotherapy NKTR-255. Nektar also received a boost from news th...

Read the whole news NKTR - Why Nektar Therapeutics Stock Popped Today

[whytestocks]

News: $NKTR Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

SAN FRANCISCO , Dec. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61 st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, NKTR-255. Data were presented fr...

In case you are interested NKTR - Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

[whytestocks]

News: $NKTR Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

SAN FRANCISCO , Nov. 10, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory (Treg) cell stimulator in development for the treatment of autoimmune and other chronic inflammato...

Read the whole news NKTR - Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

[whytestocks]

News: $NKTR Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO , Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clin...

Got this from NKTR - Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

[ClayTrader]

* * $NKTR Video Chart 10-08-2019 * *

Link to Video - click here to watch the technical chart video

[behindthebid]

Everything You Need For Your Premarket Including Nektar

Nektar had some manufacturing issues for its cancer drug, certainly hurting company credibility. Every day there is a Premarket Breakfast post with what's going on, why, gappers and sentiment. Today's Post is at

https://www.behindthebid.com/posts/premarket-breakfast-for-friday-august-9th